Nuvalent (NUVL) CDO exercises options and sells 23,000 shares
Nuvalent's Chief Development Officer, Darlene Noci, exercised stock options for 23,000 shares of Class A Common Stock on July 1, 2026, at exercise prices of $72.35 and $18.93 per share. Immediately after, she sold all 23,000 shares in an open-market transaction at a weighted average price of $123.59 per share. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 18, 2024, leaving her with 58,117 directly owned shares.
Nuvalent (NUVL) CFO sells 11,430 shares and exercises options under plan
Nuvalent, Inc.'s CFO, Alexandra Balcom, exercised stock options for 11,430 shares and subsequently sold the same number of shares (11,430) at a weighted average price of $123.58 per share. These transactions were executed on July 1, 2026, under a Rule 10b5-1 trading plan adopted in December 2025. Following these trades, Balcom directly holds 85,533 shares and retains additional stock options.
NUVL (NASDAQ: NUVL) Form 144 lists insider sale of Class A Common
Nuvalent, Inc. (NUVL) has filed a Form 144 with the SEC, indicating a proposed insider sale of Class A Common shares via NQ Stock Options, with J.P. Morgan Securities LLC named as the broker. The filing also details multiple past sales attributed to Alexandra Balcom, occurring between March and June 2026. This notice provides transparency regarding planned and previous insider transactions, with the proposed sale entry date listed as July 1, 2026.
Insider at Nuvalent (NUVL) exercises options and sells 5,500 shares
Nuvalent's Chief Development Officer, Darlene Noci, exercised stock options to acquire 5,500 shares at $27.85 per share and subsequently sold those 5,500 shares in the open market for a weighted average price of $123.51 per share. These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on November 18, 2024. Following the sale, Noci directly holds 58,117 shares of Nuvalent Class A Common Stock.
GSK plc (GSK) Launches Tender Offer to Acquire Nuvalent Inc. for $124 Per Share
GSK plc has launched a tender offer to acquire Nuvalent, Inc. for $124 per share in cash, following a merger agreement signed on June 9, 2026. This move represents a significant step in GSK's strategic acquisitions. Additionally, GSK's ViiV Healthcare has introduced the PrEP Wisdom campaign to enhance understanding of long-acting injectable HIV prevention.
Enterprise value to revenue forward of Nuvalent, Inc. Class A – FWB:5AX
This article provides financial information for Nuvalent, Inc. Class A, specifically its enterprise value to revenue (forward) metric. The content indicates that the market was closed and no trades were made for this stock. The data is provided by ICE Data Services and FactSet Research Systems Inc.
Price to book forward of Nuvalent, Inc. Class A – FWB:5AX
This article provides financial information for Nuvalent, Inc. Class A, traded on the Frankfurt Stock Exchange (FWB:5AX). It specifically highlights the "Price to book forward" metric. The content itself seems to be a placeholder or a snippet from a financial data platform, showing no specific numerical values for the metric.
Nuvalent, Inc. Class A Actuals & Estimates (NASDAQ:NUVL)
This article provides an overview of Nuvalent, Inc. (NASDAQ: NUVL) stock's actuals and estimates, including its current stock price, historical performance, analyst forecasts, and various financial metrics. It details the company's market capitalization, earnings per share, revenue, net income, and upcoming earnings report date. The article also addresses frequently asked questions about the stock's volatility, dividend policy, and how to trade its shares.
Price to earnings forward of Nuvalent, Inc. Class A – FWB:5AX
This article provides financial information for Nuvalent, Inc. Class A, traded on the Frankfurt Stock Exchange under the symbol FWB:5AX. It specifically highlights the "Price to earnings forward" metric for the company. The content appears to be a financial data page from TradingView, focusing on key financial metrics for this pharmaceutical stock.
Enterprise value to EBITDA forward of Nuvalent, Inc. Class A – FWB:5AX
This article provides financial information for Nuvalent, Inc. Class A (FWB:5AX), specifically its enterprise value to EBITDA forward. It notes that the market was closed with no trades. The data is made available through TradingView, sourcing information from ICE Data Services and FactSet.
GSK (NYSE: GSK) moves to acquire Nuvalent with $124/share cash tender offer
GSK has launched a cash tender offer to acquire all outstanding Class A and Class B shares of Nuvalent, Inc. for $124.00 per share. This acquisition, made through its subsidiary Harmony Row Acquisition Co., is structured to be followed by a merger, making Nuvalent a wholly-owned subsidiary of GSK LLC. Nuvalent's board has recommended that its stockholders accept the offer, which is set to expire on July 14, 2026, and is contingent on a minimum tender condition and regulatory approvals.
GSK (NUVL) bidders launch $124.00 cash tender for Nuvalent shares
Harmony Row Acquisition Co., a subsidiary of GlaxoSmithKline LLC and GSK plc, has launched a cash tender offer to acquire all outstanding Class A and Class B shares of Nuvalent, Inc. for $124.00 per share. This offer is detailed in an amended Schedule TO filing, which incorporates the Offer to Purchase and Letter of Transmittal dated June 24, 2026, and a press release from GSK plc. The transaction provides immediate liquidity to Nuvalent shareholders at a fixed price, with the offer being net to sellers and subject to conditions outlined in the Merger Agreement.
GSK announces commencement of tender offer to acquire Nuvalent, Inc.
GSK has commenced a tender offer to acquire all outstanding shares of Nuvalent, Inc. for $124.00 per share in cash. The acquisition will proceed through a direct wholly-owned subsidiary, Harmony Row Acquisition Co., and will lead to Nuvalent becoming a wholly-owned subsidiary of GSK LLC. Nuvalent's Board of Directors recommends that stockholders accept the offer, which is set to expire on July 14, 2026, subject to certain conditions.
GSK plc (NUVL) offers $124.00 per share in cash tender for Nuvalent
GSK plc, GlaxoSmithKline LLC, and Harmony Row Acquisition Co. are tendering an offer to purchase all outstanding Class A and Class B shares of Nuvalent, Inc. for $124.00 per share in cash. The offer, detailed in a Schedule TO filing, is subject to the terms of the Offer to Purchase and an Agreement and Plan of Merger dated June 9, 2026. As of June 17, 2026, Nuvalent had 73,899,592 Class A shares and 5,435,254 Class B shares outstanding.
Nuvalent (NUVL) director Ron Squarer receives 3,444 RSUs in equity award
Nuvalent (NUVL) director Ron Squarer was granted an equity award of 3,444 restricted stock units (RSUs) on June 16, 2026. These RSUs, which convert into Class A Common Stock at no purchase price, will vest in full on the earlier of June 16, 2027, or the date of the next annual stockholders' meeting, provided Squarer continues his service. Following this transaction, Squarer's direct holdings in Nuvalent total 6,281 shares.
Nuvalent (NUVL) director granted 3,444 RSUs in new equity award
Nuvalent, Inc. director Sapna Srivastava was granted 3,444 restricted stock units (RSUs) of Class A Common Stock as a new equity award. These RSUs will vest in full on the earlier of June 16, 2027, or the company's next annual meeting, provided she continues her service. Following this grant, Srivastava directly holds 8,590 shares of Class A Common Stock.
Nuvalent (NUVL) director Anna Protopapas receives 3,444 RSUs in equity grant
Nuvalent, Inc. director Anna Protopapas was granted 3,444 restricted stock units (RSUs) of Class A Common Stock, as disclosed in a Form 4 filing. The grant, valued at $0.00 per share, is a compensation award and not a market transaction. Following this award, Protopapas directly holds 8,590 shares, with the RSUs scheduled to vest on June 16, 2027, or at the next annual shareholders' meeting, whichever comes first.
Nuvalent (NUVL) director Oliger awarded 3,444 RSUs, total holdings 7,415 shares
Nuvalent, Inc. director Christy J. Oliger was granted 3,444 Class A Common Stock Restricted Stock Units (RSUs) as compensation, bringing her total direct holdings to 7,415 shares. These RSUs vest in full on the earlier of June 16, 2027, or the company's next annual stockholder meeting, contingent on her continued service. The transaction was reported in a Form 4 filing, indicating an acquisition of equity-based compensation rather than a market trade.
Nuvalent (NUVL) director reports 3,444-share RSU equity award holding 8,590 total
Nuvalent, Inc. director Cameron Wheeler was granted 3,444 shares of Class A Common Stock in the form of restricted stock units (RSUs), bringing his total reported RSU holding to 8,590 shares. The award was granted at no cash cost and vests in full on the earlier of June 16, 2027, or the company's next annual stockholder meeting, contingent on continued service. Wheeler, a partner with Deerfield Management Company, L.P., holds these securities for Deerfield's benefit and disclaims pecuniary interest.
Director at Nuvalent (NUVL) receives 3,444 RSUs in equity grant
Nuvalent, Inc. director Michael L. Meyers received an equity grant of 3,444 restricted stock units (RSUs) of Class A Common Stock at no cash cost. These RSUs will vest on the earlier of June 16, 2027, or the next annual stockholder meeting, contingent on his continued service. Following this grant, Meyers directly holds 8,590 shares of Nuvalent.
Nuvalent (NUVL) director Grant C. Bogle receives 3,444 RSU award
Nuvalent, Inc. director Grant C. Bogle was granted 3,444 restricted stock units (RSUs) of Class A Common Stock as compensation, not a market purchase. The RSUs, valued at $0.00 per share, will vest fully on June 16, 2027, or at the next annual stockholders' meeting, provided Bogle remains with the company. This award increases his direct holdings to 9,291 shares.
Why Nuvalent Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket
Nuvalent, Inc. (NASDAQ:NUVL) shares surged by 38.2% in pre-market trading after GSK announced an agreement to acquire the company for $10.6 billion, representing a 40% premium. The article also lists other stocks experiencing significant pre-market movements, both gains and losses, influenced by various corporate announcements and market dynamics.
UPDATE 1-Project Nashville: GSK boosts oncology rebuild with $11 billion Nuvalent deal
GSK has made its largest acquisition to date, an $11 billion deal for Nuvalent, to accelerate the rebuild of its oncology business and counter patent cliffs for other drugs. The acquisition, codenamed Nashville, adds two late-stage lung cancer treatments that could be approved this year, aligning with CEO Luke Miels' strategy to expand GSK's presence in oncology. While investors see the deal as a significant step, some note that GSK still needs to do more to catch up with rivals like AstraZeneca and Roche in the oncology market.
Nuvalent (NUVL) CDO sells 20,000 shares, exercises options
Nuvalent's Chief Development Officer, Darlene Noci, reported exercising stock options for 20,000 shares and subsequently selling 20,000 shares of Class A Common Stock on June 9, 2026, as per a pre-arranged Rule 10b5-1 trading plan. The shares were sold at an average price of $122.81, and after these transactions, Noci directly holds 58,117 shares. This activity is considered neutral in terms of filing impact and sentiment.
GSK agrees to acquire Nuvalent, Inc.
GSK plc has announced an agreement to acquire Boston-based biopharmaceutical company Nuvalent, Inc. This acquisition includes three lung cancer products, two of which are late-stage ROS1 and ALK inhibitors for NSCLC currently under US FDA review for 2026 approvals. The deal aligns with GSK's strategy to acquire assets that address efficacy or tolerability limitations in existing standard therapies and offers immediate new sales growth opportunities and a platform for expansion in lung cancer.
Project Nashville: GSK boosts oncology rebuild with $11 billion Nuvalent deal
GSK has announced its largest acquisition to date, an $11 billion deal for Nuvalent, aimed at accelerating the rebuilding of its cancer drug business. This move is part of CEO Luke Miels' strategy to expand in oncology, a sector GSK exited a decade ago, and helps offset future patent expirations. While the deal is seen as a significant step, some investors believe GSK will need further acquisitions to truly compete with established oncology rivals like AstraZeneca and Roche.
Nuvalent (NUVL) CEO nets 30K-share sale under Rule 10b5-1 plan
Nuvalent, Inc.'s President and CEO, James Richard Porter, executed an exercise-and-sell transaction on June 8, 2026, involving 30,000 shares of Class A Common Stock. This sale, conducted under a pre-established Rule 10b5-1 trading plan, occurred at weighted average prices in the high-$80 range, totaling approximately $2.66 million. Concurrently, Porter exercised stock options for the same number of shares at $18.93 per share, and following these transactions, he directly holds 354,879 shares and 148,686 stock options.
Super Micro Computer, Draftkings, Cracker Barrel, Nuvalent And Oracle: Why These 5 Stocks Are On Investors' Radars Today
This article highlights five stocks—Super Micro Computer, Draftkings, Cracker Barrel, Nuvalent, and Oracle—that have captured investor interest. Super Micro Computer saw a drop despite plans to raise capital for AI server orders, while DraftKings and Cracker Barrel experienced gains due to strong operational metrics and exceeding earnings expectations, respectively. Nuvalent surged significantly following an acquisition announcement by GSK, and Oracle declined ahead of anticipated strong fourth-quarter revenue.
GSK plc to pursue cash tender offer for Nuvalent (NASDAQ: NUVL)
GSK plc announced its intention to launch a cash tender offer to acquire all outstanding Class A and Class B shares of Nuvalent, Inc. This communication is a pre-commencement notification, meaning the formal tender offer has not yet begun. The proposed acquisition is based on an Agreement and Plan of Merger dated June 9, 2026, and shareholders will be directed to future SEC filings for complete details, including the offer price and timing once the offer commences.
GSK Enters Agreement to Acquire Nuvalent Inc June 10, 2026
GSK has announced an agreement to acquire Nuvalent, Inc. for $10.6 billion. The acquisition will expand GSK's oncology pipeline with three lung cancer products, including two late-stage, potential best-in-class inhibitors for non-small cell lung cancer (zidesamtinib and neladalkib) that are currently under US FDA review. This deal is expected to be accretive to GSK's sales and core operating profit from 2027 and core EPS from 2029.
Nuvalent, Inc. Class A Trade Ideas — FWB:5AX
This article compiles several trade ideas for Nuvalent, Inc. Class A (FWB:5AX) from various traders on TradingView. The ideas include bullish setups, breakout strategies, and technical analysis using indicators like H&S patterns, VWAP, and moving averages. Traders suggest long positions with specific entry, stop-loss, and target prices for short-term and intraday trading opportunities.
GSK plc (NYSE: GSK) to seek tender offer for Nuvalent (NUVL)
GSK plc has announced its intent to launch a cash tender offer to acquire all Class A and Class B common shares of Nuvalent, Inc. This follows an Agreement and Plan of Merger signed on June 9, 2026. The tender offer has not yet commenced, but formal statements including a Tender Offer Statement on Schedule TO and a Solicitation/Recommendation Statement on Schedule 14D-9 will be filed with the SEC when it does.
NUVL (NASDAQ: NUVL) files Rule 144 notice to sell 48,500 shares
Nuvalent, Inc. (NASDAQ: NUVL) has filed a Rule 144 notice to sell 48,500 shares of Class A Common stock, stemming from a stock option exercise on June 9, 2026, with cash as the payment method. The filing also discloses three previous sales of 5,500 shares each by Darlene Noci on March 30, April 29, and May 28, 2026. This regulatory notice is a routine compliance disclosure regarding the intent to sell securities under resale conditions.
GSK enters agreement to acquire Nuvalent, Inc.
GSK announced an agreement to acquire Nuvalent, Inc. for $10.6 billion, expanding its oncology portfolio with three lung cancer products. The acquisition includes two late-stage, potential best-in-class ROS1 and ALK inhibitors, zidesamtinib and neladalkib, for non-small cell lung cancer (NSCLC), which are under FDA review for 2026 approvals. This deal is expected to accelerate GSK's entry into lung cancer, contribute to revenue growth from 2027, and be accretive to core operating profit from 2027 and core EPS by 2029.
GSK Enters $10.6 Billion Agreement to Acquire Nuvalent Inc.
GSK has agreed to acquire Nuvalent Inc. for $10.6 billion, adding two late-stage non-small cell lung cancer (NSCLC) inhibitors, zidesamtinib and neladalkib, and an early-stage HER2 inhibitor, NVL-330, to its oncology pipeline. The acquisition also includes Nuvalent's precision medicine platform. The deal, which offers a 40% premium to Nuvalent shareholders, is expected to close in Q3 2026 and is anticipated to be slightly dilutive to GSK's core EPS through 2028, with accretion projected for 2029.
GSK plc (NUVL) plans cash tender offer for Nuvalent under merger agreement
GSK plc has announced a planned cash tender offer to acquire all issued and outstanding Class A and Class B common stock of Nuvalent, Inc. This communication is a pre-commencement Schedule TO filing, indicating that the tender offer has not yet officially launched. The acquisition is pursuant to a merger agreement dated June 9, 2026, and is subject to standard closing conditions including shareholder tender thresholds and regulatory approvals.
GSK to buy Nuvalent (NASDAQ: NUVL) for $124 per share in cash
GSK has announced an agreement to acquire Nuvalent for $124 per share in an all-cash tender offer, valuing the company's equity at approximately $10.6 billion. The acquisition includes two late-stage lung cancer therapies, zidesamtinib and neladalkib, with FDA Breakthrough Therapy and Orphan Drug Designations, expected to launch in 2026. This strategic move aims to strengthen GSK's oncology pipeline, improve revenue growth from 2027, and contribute to its core operating profit.
UPDATE 4-GSK boosts cancer portfolio with $10.6 billion Nuvalent takeover
GSK has agreed to acquire U.S.-listed cancer drug developer Nuvalent for $10.6 billion, marking its largest deal in over a decade and a strategic shift toward oncology under new CEO Luke Miels. The all-cash deal, valued at $124 per share, represents a 40% premium for Nuvalent shareholders and aims to bolster GSK's lung cancer treatment pipeline and offset the upcoming patent expiry of its HIV medicine. The acquisition is expected to add to GSK's sales and operating profit by 2027, with Nuvalent's lead drugs, zidesamtinib and neladalkib, showing multi-blockbuster potential.
NUVL (NASDAQ) registers 90,000 Class A shares after option exercise
Nuvalent, Inc. (NASDAQ: NUVL) has registered 90,000 Class A Common shares related to a stock option exercise effective June 8, 2026. The shares will be sold through J.P. Morgan Securities LLC for cash. The filing also reports previous dispositions by James Richard Porter of 30,000 shares each on April 6, 2026, and May 4, 2026.
Cost of goods sold of Nuvalent, Inc. Class A – FWB:5AX
The article displays the cost of goods sold for Nuvalent, Inc. Class A, traded on the Frankfurt Stock Exchange under the ticker FWB:5AX. It also indicates the period, value, and change in these figures, along with the percentage change. The content appears to be a financial data snippet from TradingView.
Nuvalent, Inc. Class A Trade Ideas — LSX:A3CWDU
This article compiles various trade ideas for Nuvalent, Inc. Class A (LSX:A3CWDU), offering different analyses and strategies from multiple traders. The ideas include bullish breakout setups, technical pattern recognition like Head & Shoulders, and intraday IPO trading opportunities. These insights aim to provide diverse perspectives for potential investors and traders to inform their own strategies for NUVL stock.
Working capital per share of Nuvalent, Inc. Class A – FWB:5AX
This article displays the working capital per share for Nuvalent, Inc. Class A (FWB:5AX) on the Frankfurt Stock Exchange. It indicates that the market is currently closed with no trades. The content is primarily a data display page from TradingView.
Dilution adjustment of Nuvalent, Inc. Class A – FWB:5AX
This article from TradingView briefly reports on a dilution adjustment for Nuvalent, Inc. Class A stock, listed on the Frankfurt Stock Exchange under the ticker 5AX. The content appears to be a stub or a placeholder, indicating a corporate action without providing detailed financial figures or explanation. It serves primarily as a notification within the platform's market data interface.
Nuvalent (NUVL) CFO Balcom sells 11,430 shares and exercises options under 10b5-1 plan
Nuvalent, Inc. (NUVL) CFO Alexandra Balcom sold 11,430 shares of Class A Common Stock and simultaneously exercised stock options for 11,430 shares on June 1, 2026. The stock sales occurred at weighted average prices between $94.48 and $104.19 per share, as part of a pre-arranged Rule 10b5-1 trading plan. After these transactions, Balcom retained a substantial direct ownership of 96,963 shares of Nuvalent Class A Common Stock.
Cash per share of Nuvalent, Inc. Class A – TRADEGATE:5AX
This article provides financial information for Nuvalent, Inc. Class A, specifically focusing on its cash per share data. It mentions the company's listing on the Tradegate Exchange under the symbol 5AX and refers to market data provided by ICE Data Services and FactSet.
Nuvalent (NASDAQ: NUVL) CLO sells 5,500 shares under Rule 10b5-1 plan
Nuvalent Inc.'s Chief Legal Officer, Deborah Ann Miller, executed an exercise-and-sell transaction involving 5,500 shares of Class A Common Stock on May 28, 2026. She exercised stock options at $6.89 per share and sold the shares on the open market at weighted average prices between approximately $105.87 and $109.76, following a pre-arranged Rule 10b5-1 trading plan. After these transactions, Miller retains a direct holding of 59,634 shares of Nuvalent Class A Common Stock.
Nuvalent CLO Deborah Miller sells $593,100 in stock
Deborah Ann Miller, Nuvalent's Chief Legal Officer, sold 5,500 shares of Class A Common Stock for approximately $593,100 on May 28, 2026, following the exercise of stock options. These transactions were executed under a Rule 10b5-1 trading plan. Miller now directly holds 59,634 shares of Nuvalent stock after these sales and prior option exercises.
Nuvalent (NUVL) CDO exercises options, sells 5,500 shares under 10b5-1 plan
Nuvalent, Inc.'s Chief Development Officer, Darlene Noci, exercised stock options to acquire 5,500 shares and subsequently sold 5,500 shares of Class A Common Stock on May 28, 2026. These transactions, executed under a Rule 10b5-1 trading plan adopted in November 2024, involved sales at weighted average prices ranging from $106.26 to $109.76 per share. Following these transactions, Noci directly holds 63,617 Class A Common Stock shares and 86,829 stock options.
Nuvalent Announces Key Program and Business Updates, Strengthening Foundation for Global Leadership in ROS1- and ALK-positive NSCLC
Nuvalent, Inc. announced key program and business updates, including the FDA's acceptance of its New Drug Application (NDA) for neladalkib with Priority Review for pre-treated ALK-positive NSCLC, targeting a PDUFA date of November 27, 2026. The company also appointed Georg Pirmin Meyer, M.D., as Chief International Officer to spearhead global expansion, aiming for leadership in ROS1- and ALK-positive NSCLC markets. This move positions Nuvalent to deliver multiple synergistic launches in biomarker-driven NSCLC globally, building on existing NDA reviews for both neladalkib and zidesamtinib.
Inventory turnover of Nuvalent, Inc. Class A – TRADEGATE:5AX
This article provides financial information for Nuvalent, Inc. Class A (TRADEGATE:5AX), specifically focusing on its inventory turnover. It indicates that the market was closed and directs users to additional financial data, news, and community discussions.
